reports
Catalyst Pharmaceuticals Inc: 1 director
A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen New Jersey Quality Muni Income Fd and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 November 2025 in which we reassessed the appropriateness of the...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the ™, a ranking of the 500 fastest-growing tec...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthca...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 20...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results ...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM E...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be na...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Progr...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and December 31, 202...
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
- Jonathan Moreland
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
ASYS AMTECH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
NWPP NEW PEOPLES BANKSHARES INC.
BHR BRAEMAR HOTELS & RESORTS
CCEL CRYO-CELL INTERNATIONAL
REZI RESIDEO TECHNOLOGIES
WU INC.
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
COO SELF STORAGE GROUP
REYN INC.
STTK PRECIGEN INC
ENOV THE COOPER COMPANIES INC.
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC SHATTUCK LABS
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
ISPO ENERGY TRANSFER LP
AFCG PRAIRIE OPERATING CO.
FG BAKKT HOLDINGS INC.
NIQ INSPIRATO INCORPORATED
STSS AFC GAMMA
FEAM INC.
SINT F AND G ANNUITIES AND LIFE
VWFB INC.
NIQ GLOBAL INTELLIGENCE PLC
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
VWF BANCORP
INC.
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
DIN DINE BRANDS GLOBAL INC.
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
ECIA ENCISION INC
UA UNDER ARMOUR
BHR INC.
CCEL BRAEMAR HOTELS & RESORTS
ULBI CRYO-CELL INTERNATIONAL
WU ULTRALIFE
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
REYN SELF STORAGE GROUP
OPCH INC.
ENOV PRECIGEN INC
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC OPTION CARE HEALTH INC
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
FIP ENERGY TRANSFER LP
ISPO PRAIRIE OPERATING CO.
AFCG BAKKT HOLDINGS INC.
ECF FTAI INFRASTRUCTURE INC
SST INSPIRATO INCORPORATED
STRZ AFC GAMMA
STSS INC.
FEAM ELLSWORTH FUND LTD
SINT SYSTEM1 INC
STARZ ENTERTAINMENT CORP
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
GLP GLOBAL PARTNERS LP
EMN EASTMAN CHEMICAL COMPANY
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
BHR BRAEMAR HOTELS & RESORTS
FGBI FIRST GUARANTY BANCSHARES
UONEK URBAN ONE INC CLASS D
SELF SELF STORAGE GROUP
BLIN INC.
NRGV BRIDGELINE DIGITAL INC
ONL ENERGY VAULT HOLDINGS INC
ISPO ORION OFFICE REIT INC
INSPIRATO INCORPORATED
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferenc...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. 2025 Wells Fargo H...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (a...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licenso...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifamprid...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.